Delivery Order SPE2DB22D2007-SPE2DB24FJ4KH

Award Date 7/22/24
Potential Completion Date 7/23/24
Potential Value $31K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $34,819.03, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is a Firm Fixed Price Delivery Order for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of January 6, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and...
The federal contract award, valued at $6,364.48, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for DUPIXENT 300 MG/2 ML PEN 2ML, with a firm fixed price and an ultimate completion date of January 3, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award, valued at $12,339.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract is a delivery order and is priced on a firm fixed-price basis. It has an ultimate completion date of May 12, 2023. This award is part of a larger Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $3,418.92, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
This federal contract award, valued at $71,068.61, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 200 MG/1.14 ML PEN 1.14ML, a medication, and has a completion date of November 8, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $5,594.82, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which is valued at $999,999,999 and runs through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical...
This federal contract award, valued at $11,583.43, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, a Delivery Order, is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a prescription medication. The contract has a firm fixed price and an ultimate completion date of June 3, 2024. The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds...
This is a federal contract award valued at $25,524.74 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. This contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $21,598.86 firm-fixed-price delivery order contract is for the procurement of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract has an ultimate completion date of March 13, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the...
This federal contract award, valued at $12,909.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of March 17, 2025 and is a Firm Fixed Price arrangement. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is...
  • SPE2DB22D2007
    Indefinite Delivery Contract
  • SPE2DB22D2007-SPE2DB24FJ4KH
    Delivery Order

This federal contract award, valued at $31,004.60, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is for the delivery of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML and has a completion date of July 23, 2024.

The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/17/25, 9:42 AM